Triplatin tetranitrate (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Triplatin tetranitrate" in English language version.

refsWebsite

Global rank English rank

6doi.org

2^nd place

5nih.gov

4^th place

3semanticscholar.org

11^th place

8^th place

doi.org

Tesoriero MA (2025). "What happened to BBR3464 and where to from here for multinucelar platinum-based anticancer drugs?". Dalton Transactions. 54: 2199–2208. doi:10.1039/d4dt02868f.
Farrell NP (December 2015). "Multi-platinum anti-cancer agents. Substitution-inert compounds for tumor selectivity and new targets". Chemical Society Reviews. 44 (24): 8773–85. doi:10.1039/c5cs00201j. PMID 25951946. S2CID 5171072.
Farrell NP (2012). "Progress in Platinum-Derived Drug Development". Drugs of the Future. 37 (11): 795–806. doi:10.1358/dof.2012.037.011.1830167. S2CID 75603138.
Hampton JD, Peterson EJ, Katner SJ, Turner TH, Alzubi MA, Harrell JC, Dozmorov MG, Gigliotti PJ, et al. (2022). "Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer". Mol. Cancer Ther. 21: 271–281. doi:10.1158/1535-7163.MCT-20-0969. PMC 8828673. PMID 34815360.
Gourley C, Cassidy J, Edwards C, Samuel L, Bisset D, Camboni G, et al. (February 2004). "A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer". Cancer Chemotherapy and Pharmacology. 53 (2): 95–101. doi:10.1007/s00280-003-0721-x. PMID 14605864. S2CID 19707262.
Sessa C, Capri G, Gianni L, Peccatori F, Grasselli G, Bauer J, et al. (August 2000). "Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex". Annals of Oncology. 11 (8): 977–83. doi:10.1023/a:1008302309734. PMID 11038034.

nih.gov

pubmed.ncbi.nlm.nih.gov

Farrell NP (December 2015). "Multi-platinum anti-cancer agents. Substitution-inert compounds for tumor selectivity and new targets". Chemical Society Reviews. 44 (24): 8773–85. doi:10.1039/c5cs00201j. PMID 25951946. S2CID 5171072.
Hampton JD, Peterson EJ, Katner SJ, Turner TH, Alzubi MA, Harrell JC, Dozmorov MG, Gigliotti PJ, et al. (2022). "Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer". Mol. Cancer Ther. 21: 271–281. doi:10.1158/1535-7163.MCT-20-0969. PMC 8828673. PMID 34815360.
Gourley C, Cassidy J, Edwards C, Samuel L, Bisset D, Camboni G, et al. (February 2004). "A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer". Cancer Chemotherapy and Pharmacology. 53 (2): 95–101. doi:10.1007/s00280-003-0721-x. PMID 14605864. S2CID 19707262.
Sessa C, Capri G, Gianni L, Peccatori F, Grasselli G, Bauer J, et al. (August 2000). "Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex". Annals of Oncology. 11 (8): 977–83. doi:10.1023/a:1008302309734. PMID 11038034.

ncbi.nlm.nih.gov

Hampton JD, Peterson EJ, Katner SJ, Turner TH, Alzubi MA, Harrell JC, Dozmorov MG, Gigliotti PJ, et al. (2022). "Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer". Mol. Cancer Ther. 21: 271–281. doi:10.1158/1535-7163.MCT-20-0969. PMC 8828673. PMID 34815360.

semanticscholar.org

api.semanticscholar.org

Farrell NP (December 2015). "Multi-platinum anti-cancer agents. Substitution-inert compounds for tumor selectivity and new targets". Chemical Society Reviews. 44 (24): 8773–85. doi:10.1039/c5cs00201j. PMID 25951946. S2CID 5171072.
Farrell NP (2012). "Progress in Platinum-Derived Drug Development". Drugs of the Future. 37 (11): 795–806. doi:10.1358/dof.2012.037.011.1830167. S2CID 75603138.
Gourley C, Cassidy J, Edwards C, Samuel L, Bisset D, Camboni G, et al. (February 2004). "A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer". Cancer Chemotherapy and Pharmacology. 53 (2): 95–101. doi:10.1007/s00280-003-0721-x. PMID 14605864. S2CID 19707262.